Arcutis Biotherapeutics Inc Stock

$13.61

1.64% today

Nasdaq, Jul 08, 07:19 pm CET

ISIN

US03969K1088

Symbol

ARQT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Arcutis Biotherapeutics Inc Stock price

$13.39

-18.61 58.16% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

-0.43 3.11%

ISIN

US03969K1088

Symbol

ARQT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$1.6b

Enterprise Value

$1.5b

Net debt

positive

Cash

$198.1m

Shares outstanding

119.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

7.5 | 5.0

EV/Sales

7.1 | 4.8

EV/FCF

negative

P/B

11.2

Financial Health

Equity Ratio

45.2%

Return on Equity

-88.9%

ROCE

-48.0%

ROIC

Debt/Equity

0.8

Financials (TTM | estimate)

Revenue

$212.8m | $316.7m

EBITDA

$-115.9m | $-62.9m

EBIT

$-121.3m | $-66.0m

Net Income

$-129.7m | $-68.2m

Free Cash Flow

$-116.7m

Growth (TTM | estimate)

Revenue

100.0% | 61.2%

EBITDA

40.5% | 50.0%

EBIT

38.3% | 48.6%

Net Income

40.3% | 51.3%

Free Cash Flow

41.3%

EPS

$-1.0

FCF per Share

$-1.0

Short interest

19.3%

Employees

342

Rev per Employee

$570.0k

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Get Started for Free Today

Arcutis Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

12x Buy

92%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Arcutis Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	213 213	100% 100% 100%
- Direct Costs	25 25	231% 231% 12%
Gross Profit	188 188	90% 90% 88%
- Selling and Administrative Expenses	239 239	21% 21% 112%
- Research and Development Expense	71 71	28% 28% 33%
EBITDA	-116 -116	41% 41% -54%
- Depreciation and Amortization	5.37 5.37	256% 256% 3%
EBIT (Operating Income) EBIT	-121 -121	38% 38% -57%
Net Profit	-130 -130	40% 40% -61%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Arcutis Biotherapeutics Inc Stock News

Neutral

GlobeNewsWire

●

5 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock units of Arcutis' common stock to two newly hired employees. These awards were approved by the Compensation Co...

Positive

Seeking Alpha

●

11 days ago

Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction

Arcutis Biotherapeutics' ZORYVE (roflumilast) offers superior efficacy and safety over current topical treatments for mild-to-moderate atopic dermatitis. The atopic dermatitis market is large and shifting away from steroids, positioning Arcutis to capture significant share, especially via primary care channels. Arcutis is financially strong, with over 30 months of cash runway and no anticipated...

Neutral

GlobeNewsWire

●

12 days ago

Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD) Recommendation reflects ZORYVE's proven efficacy, safety, and tolerability as a next-generation, steroid-free, topical phosphodiesterase-4 (PDE4) inhibitor Among newly evaluated branded topical therapies, ZORYVE ...

More Arcutis Biotherapeutics Inc News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.

Head office	United States
CEO	Todd Watanabe
Employees	342
Founded	2016
Website	arcutis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now